Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04354012 · ClinicalTrials.gov registry record · Phase 2
Hidradenitis Suppurativa Wound Care
A Phase 2 study of Hidradenitis Suppurativa (HS), sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT04354012 is a Phase 2 study of Hidradenitis Suppurativa (HS) that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 5 participants, below the 180-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04354012, a Phase 2 study of Hidradenitis Suppurativa (HS), has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this case series is to monitor time and outcome of healing of wounds associated with HS using Endoform \[ovine forestomach\], Hydrofera Blue \[methylene blue and gentian violet\], and Hypafix tape. a combination methylene blue, gentian violet, and ovine forestomach wound care product.
Conditions Studied
Interventions
- COMBINATION_PRODUCT methylene blue, gentian violet, and ovine forestomach wound dressings
Study Locations (1)
North Carolina
- Wake Forest Health Sciences Dermatology - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-02-04 |
| Est. Completion | 2024-08-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04354012
The ClinicalTrials.gov registry entry for NCT04354012 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 180-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (97% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 1 intervention - of which methylene blue, gentian violet, and ovine forestomach wound dressings is the first listed.
NCT04354012 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04354012 about?
NCT04354012 is a clinical study titled "Hidradenitis Suppurativa Wound Care". The objective of this case series is to monitor time and outcome of healing of wounds associated with HS using Endoform \[ovine forestomach\], Hydrofera Blue \[methylene blue and gentian violet\], and Hypafix tape. a combination methylene blue, gentian violet, and ovine forestomach wound care produc...
What is the current status of trial NCT04354012?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2021-02-04. Estimated completion is 2024-08-28.
What conditions does trial NCT04354012 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).
What interventions are being tested in trial NCT04354012?
The interventions under investigation include: methylene blue, gentian violet, and ovine forestomach wound dressings (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04354012?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04354012 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa (HS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
RECRUITING · Phase 2
-
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
RECRUITING · Phase 2
-
The Safety and Efficacy of Roflumilast Foam in HS
RECRUITING · Phase 2
-
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.